+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CRBSI Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 250 Pages
  • March 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 6055892
Description Jump to:
The catheter-related bloodstream infection (CRBSI) treatment market is set for substantial expansion, driven by the increasing prevalence of chronic diseases and advancements in medical technologies. CRBSI is a severe systemic infection that arises due to the invasion of microorganisms into the bloodstream through indwelling catheters. Effective treatment involves timely intervention, including catheter removal, administration of antibiotics, and supportive care.

Market Insights

The global CRBSI treatment market is projected to grow at a CAGR of 5.66%, reaching a valuation of $1.67 billion by 2025 and further expanding to $2.456 billion by 2032. Market growth is propelled by rising healthcare expenditures, technological advancements in catheter materials, and an increased focus on infection control measures. Innovations such as antimicrobial coatings and smart monitoring technologies for catheters are enhancing treatment efficacy and patient safety.

Market Growth Drivers

  • Rising Chronic Illnesses and Extended Catheter Use: Increasing cases of cancer, kidney failure, and cardiovascular diseases necessitate prolonged catheter use, thereby elevating the risk of CRBSI.
  • Technological Advancements: The development of antimicrobial catheters, smart monitoring technologies, and improved catheter coatings is reducing infection risks.
  • Increased Awareness and Regulatory Compliance: Strict infection control protocols and enhanced awareness among healthcare professionals are ensuring effective treatment adoption.

Market Restraints

  • Antibiotic Resistance: The emergence of drug-resistant bacterial strains is limiting treatment options, compelling healthcare providers to seek advanced and costly therapies.
  • Economic Burden on Healthcare Systems: The high cost associated with hospitalization, diagnostic procedures, and prolonged treatments adds financial strain on healthcare systems.

Business Opportunities

  • Advancements in Catheter Construction: The integration of antimicrobial materials such as silver nanoparticles and biocompatible substances is creating growth avenues.
  • Increased Research & Development: Pharmaceutical companies are focusing on developing next-generation antibiotics and antifungals to combat CRBSI more effectively.
  • Rising Adoption of Digital Healthcare: The growing penetration of online pharmacies and telemedicine services is streamlining CRBSI treatment accessibility.

Regional Analysis

  • North America: Expected to dominate the market due to well-established healthcare infrastructure, strong regulatory frameworks, and high healthcare spending. The region’s emphasis on infection control and advanced R&D is further driving market growth.
  • Asia Pacific: Poised for the fastest growth, fueled by rising healthcare expenditure, urbanization, and an increasing geriatric population. Nations such as China and Japan are witnessing enhanced access to advanced medical treatments.
  • Europe: The region is experiencing steady growth due to improved healthcare policies and increasing focus on infection control measures.
  • Latin America and Middle East & Africa: These regions are gradually expanding due to the rising prevalence of chronic diseases and growing investments in healthcare infrastructure.

Key Players and Competitive Analysis

Leading pharmaceutical companies are leveraging innovation and strategic partnerships to strengthen their market position. Major players include:

  • Pfizer Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • GSK plc
  • Sanofi AG
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • Fresenius SE & Co. KGaA
  • Aurobindo Pharma Limited
  • Mylan N.V. (Viatris)
  • B. Braun Medical Inc.
  • SteriMax Inc.

Market Segmentation

By Drug Class:

  • Cloxacillin
  • Ceftazidime
  • Cefazoline
  • Daptomycin
  • Vancomycin
  • Teicoplanin
  • Echinocandin
  • Others

By Route of Administration:

  • Oral
  • Injectable

By Indication:

  • Bacterial Infections
  • Fungal Infection
  • Viral and Parasitic Infections

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global CRBSI Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global CRBSI Treatment Market Outlook, 2019 - 2032
3.1. Global CRBSI Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2032
3.1.1. Key Highlights
3.1.1.1. Cloxacillin
3.1.1.2. Ceftazidime
3.1.1.3. Cefazoline
3.1.1.4. Daptomycin
3.1.1.5. Vancomycin
3.1.1.6. Teicoplanin
3.1.1.7. Echinocandin
3.1.1.8. Others
3.2. Global CRBSI Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2032
3.2.1. Key Highlights
3.2.1.1. Oral
3.2.1.2. Injectable
3.3. Global CRBSI Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2032
3.3.1. Key Highlights
3.3.1.1. Bacterial Infections
3.3.1.2. Fungal Infection
3.3.1.3. Viral and Parasitic Infections
3.4. Global CRBSI Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
3.4.1. Key Highlights
3.4.1.1. Hospital Pharmacies
3.4.1.2. Retail Pharmacies
3.5. Global CRBSI Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America CRBSI Treatment Market Outlook, 2019 - 2032
4.1. North America CRBSI Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2032
4.1.1. Key Highlights
4.1.1.1. Cloxacillin
4.1.1.2. Ceftazidime
4.1.1.3. Cefazoline
4.1.1.4. Daptomycin
4.1.1.5. Vancomycin
4.1.1.6. Teicoplanin
4.1.1.7. Echinocandin
4.1.1.8. Others
4.2. North America CRBSI Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2032
4.2.1. Key Highlights
4.2.1.1. Oral
4.2.1.2. Injectable
4.3. North America CRBSI Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2032
4.3.1. Key Highlights
4.3.1.1. Bacterial Infections
4.3.1.2. Fungal Infection
4.3.1.3. Viral and Parasitic Infections
4.4. North America CRBSI Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
4.4.1. Key Highlights
4.4.1.1. Hospital Pharmacies
4.4.1.2. Retail Pharmacies
4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America CRBSI Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
4.5.1. Key Highlights
4.5.1.1. U.S. CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
4.5.1.2. U.S. CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
4.5.1.3. U.S. CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
4.5.1.4. U.S. CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
4.5.1.5. Canada CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
4.5.1.6. Canada CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
4.5.1.7. Canada CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
4.5.1.8. Canada CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe CRBSI Treatment Market Outlook, 2019 - 2032
5.1. Europe CRBSI Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2032
5.1.1. Key Highlights
5.1.1.1. Cloxacillin
5.1.1.2. Ceftazidime
5.1.1.3. Cefazoline
5.1.1.4. Daptomycin
5.1.1.5. Vancomycin
5.1.1.6. Teicoplanin
5.1.1.7. Echinocandin
5.1.1.8. Others
5.2. Europe CRBSI Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2032
5.2.1. Key Highlights
5.2.1.1. Oral
5.2.1.2. Injectable
5.3. Europe CRBSI Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2032
5.3.1. Key Highlights
5.3.1.1. Bacterial Infections
5.3.1.2. Fungal Infection
5.3.1.3. Viral and Parasitic Infections
5.4. Europe CRBSI Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.4.1. Key Highlights
5.4.1.1. Hospital Pharmacies
5.4.1.2. Retail Pharmacies
5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe CRBSI Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
5.5.1. Key Highlights
5.5.1.1. Germany CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
5.5.1.2. Germany CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
5.5.1.3. Germany CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
5.5.1.4. Germany CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.5. U.K. CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
5.5.1.6. U.K. CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
5.5.1.7. U.K. CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
5.5.1.8. U.K. CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.9. France CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
5.5.1.10. France CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
5.5.1.11. France CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
5.5.1.12. France CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.13. Italy CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
5.5.1.14. Italy CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
5.5.1.15. Italy CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
5.5.1.16. Italy CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.17. Turkey CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
5.5.1.18. Turkey CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
5.5.1.19. Turkey CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
5.5.1.20. Turkey CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.21. Russia CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
5.5.1.22. Russia CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
5.5.1.23. Russia CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
5.5.1.24. Russia CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.1.25. Rest of Europe CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
5.5.1.26. Rest of Europe CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
5.5.1.27. Rest of Europe CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
5.5.1.28. Rest of Europe CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific CRBSI Treatment Market Outlook, 2019 - 2032
6.1. Asia Pacific CRBSI Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2032
6.1.1. Key Highlights
6.1.1.1. Cloxacillin
6.1.1.2. Ceftazidime
6.1.1.3. Cefazoline
6.1.1.4. Daptomycin
6.1.1.5. Vancomycin
6.1.1.6. Teicoplanin
6.1.1.7. Echinocandin
6.1.1.8. Others
6.2. Asia Pacific CRBSI Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2032
6.2.1. Key Highlights
6.2.1.1. Oral
6.2.1.2. Injectable
6.3. Asia Pacific CRBSI Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2032
6.3.1. Key Highlights
6.3.1.1. Bacterial Infections
6.3.1.2. Fungal Infection
6.3.1.3. Viral and Parasitic Infections
6.4. Asia Pacific CRBSI Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.4.1. Key Highlights
6.4.1.1. Hospital Pharmacies
6.4.1.2. Retail Pharmacies
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific CRBSI Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
6.5.1. Key Highlights
6.5.1.1. China CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
6.5.1.2. China CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
6.5.1.3. China CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
6.5.1.4. China CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.5. Japan CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
6.5.1.6. Japan CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
6.5.1.7. Japan CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
6.5.1.8. Japan CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.9. South Korea CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
6.5.1.10. South Korea CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
6.5.1.11. South Korea CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
6.5.1.12. South Korea CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.13. India CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
6.5.1.14. India CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
6.5.1.15. India CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
6.5.1.16. India CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.17. Southeast Asia CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
6.5.1.18. Southeast Asia CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
6.5.1.19. Southeast Asia CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
6.5.1.20. Southeast Asia CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.1.21. Rest of Asia Pacific CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
6.5.1.22. Rest of Asia Pacific CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
6.5.1.23. Rest of Asia Pacific CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
6.5.1.24. Rest of Asia Pacific CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America CRBSI Treatment Market Outlook, 2019 - 2032
7.1. Latin America CRBSI Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2032
7.1.1. Key Highlights
7.1.1.1. Cloxacillin
7.1.1.2. Ceftazidime
7.1.1.3. Cefazoline
7.1.1.4. Daptomycin
7.1.1.5. Vancomycin
7.1.1.6. Teicoplanin
7.1.1.7. Echinocandin
7.1.1.8. Others
7.2. Latin America CRBSI Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2032
7.2.1. Key Highlights
7.2.1.1. Oral
7.2.1.2. Injectable
7.3. Latin America CRBSI Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2032
7.3.1. Key Highlights
7.3.1.1. Bacterial Infections
7.3.1.2. Fungal Infection
7.3.1.3. Viral and Parasitic Infections
7.4. Latin America CRBSI Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.4.1. Key Highlights
7.4.1.1. Hospital Pharmacies
7.4.1.2. Retail Pharmacies
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America CRBSI Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
7.5.1. Key Highlights
7.5.1.1. Brazil CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
7.5.1.2. Brazil CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
7.5.1.3. Brazil CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
7.5.1.4. Brazil CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.5.1.5. Mexico CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
7.5.1.6. Mexico CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
7.5.1.7. Mexico CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
7.5.1.8. Mexico CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.5.1.9. Argentina CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
7.5.1.10. Argentina CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
7.5.1.11. Argentina CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
7.5.1.12. Argentina CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.5.1.13. Rest of Latin America CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
7.5.1.14. Rest of Latin America CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
7.5.1.15. Rest of Latin America CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
7.5.1.16. Rest of Latin America CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa CRBSI Treatment Market Outlook, 2019 - 2032
8.1. Middle East & Africa CRBSI Treatment Market Outlook, by Drug Class, Value (US$ Bn), 2019 - 2032
8.1.1. Key Highlights
8.1.1.1. Cloxacillin
8.1.1.2. Ceftazidime
8.1.1.3. Cefazoline
8.1.1.4. Daptomycin
8.1.1.5. Vancomycin
8.1.1.6. Teicoplanin
8.1.1.7. Echinocandin
8.1.1.8. Others
8.2. Middle East & Africa CRBSI Treatment Market Outlook, by Route of Administration, Value (US$ Bn), 2019 - 2032
8.2.1. Key Highlights
8.2.1.1. Nuclear Transferase
8.2.1.2. Microinjection
8.2.1.3. Embryonic Stem Cell
8.2.1.4. Others
8.3. Middle East & Africa CRBSI Treatment Market Outlook, by Indication, Value (US$ Bn), 2019 - 2032
8.3.1. Key Highlights
8.3.1.1. Bacterial Infections
8.3.1.2. Fungal Infection
8.3.1.3. Viral and Parasitic Infections
8.4. Middle East & Africa CRBSI Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.4.1. Key Highlights
8.4.1.1. Hospital Pharmacies
8.4.1.2. Retail Pharmacies
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa CRBSI Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
8.5.1. Key Highlights
8.5.1.1. GCC CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
8.5.1.2. GCC CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
8.5.1.3. GCC CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
8.5.1.4. GCC CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.1.5. South Africa CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
8.5.1.6. South Africa CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
8.5.1.7. South Africa CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
8.5.1.8. South Africa CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.1.9. Egypt CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
8.5.1.10. Egypt CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
8.5.1.11. Egypt CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
8.5.1.12. Egypt CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.1.13. Nigeria CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
8.5.1.14. Nigeria CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
8.5.1.15. Nigeria CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
8.5.1.16. Nigeria CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.1.17. Rest of Middle East & Africa CRBSI Treatment Market by Drug Class, Value (US$ Bn), 2019 - 2032
8.5.1.18. Rest of Middle East & Africa CRBSI Treatment Market by Route of Administration, Value (US$ Bn), 2019 - 2032
8.5.1.19. Rest of Middle East & Africa CRBSI Treatment Market by Indication, Value (US$ Bn), 2019 - 2032
8.5.1.20. Rest of Middle East & Africa CRBSI Treatment Market by Distribution Channel, Value (US$ Bn), 2019 - 2032
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Manufacturer vs by Route of Administration Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Aurobindo Pharma Limited
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. B. Braun Medical Inc.
9.4.3. Eli Lilly and Company
9.4.4. Fresenius SE & Co. KGaA
9.4.5. GSK plc
9.4.6. Merck & Co., Inc.
9.4.7. Mylan N.V. (Viatris)
9.4.8. Novartis
9.4.9. Pfizer Inc.
9.4.10. Sanofi AG
9.4.11. SteriMax Inc.
9.4.12. Teva Pharmaceutical Industries Ltd.
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Aurobindo Pharma Limited
  • B. Braun Medical Inc.
  • Eli Lilly and Company
  • Fresenius SE & Co. KGaA
  • GSK plc
  • Merck & Co., Inc.
  • Mylan N.V. (Viatris)
  • Novartis
  • Pfizer Inc.
  • Sanofi AG
  • SteriMax Inc.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Catheter Related Bloodstream Infections Market Report and Forecast 2024-2032 - Product Image

Catheter Related Bloodstream Infections Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Catheter-Related Bloodstream Infections (CRBSIs) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034? - Product Image

Catheter-Related Bloodstream Infections (CRBSIs) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?

  • Report
  • 128 Pages
  • Global
From
Catheter-Related Bloodstream Infection Market Report 2025 - Product Image

Catheter-Related Bloodstream Infection Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Central Venous Catheter Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Central Venous Catheter Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Catheter Related Bloodstream Infection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Catheter Related Bloodstream Infection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.